{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,15]],"date-time":"2026-10-15T06:59:35Z","timestamp":1792047575492,"version":"4.4.0"},"reference-count":36,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2020,4,6]],"date-time":"2020-04-06T00:00:00Z","timestamp":1586131200000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"},{"start":{"date-parts":[[2020,4,6]],"date-time":"2020-04-06T00:00:00Z","timestamp":1586131200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100003725","name":"National Research Foundation of Korea","doi-asserted-by":"crossref","award":["NRF-2017R1A1A3A04069314"],"award-info":[{"award-number":["NRF-2017R1A1A3A04069314"]}],"id":[{"id":"10.13039\/501100003725","id-type":"DOI","asserted-by":"crossref"}]},{"name":"Ministry of Health & Welfare, Republic of Korea","award":["HI17C0904"],"award-info":[{"award-number":["HI17C0904"]}]},{"name":"Ulsan University Hospital Research Grant","award":["UUH-2019-06"],"award-info":[{"award-number":["UUH-2019-06"]}]},{"name":"Ulsan University Hospital","award":["UUHBRC-2016-001"],"award-info":[{"award-number":["UUHBRC-2016-001"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Cancer"],"published-print":{"date-parts":[[2020,12]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Leukemia stem cells (LSCs) in play an important role in the initiation, relapse, and progression of acute myeloid leukemia (AML), and in the development of chemotherapeutic drug resistance in AML. Studies regarding the detection of LSCs and the development of novel therapies for targeting them are extensive. The identification of LSCs and targeting therapies for them has been continuously under investigation.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>\n                      We examined the levels of CD45\n                      <jats:sup>dim<\/jats:sup>\n                      CD34\n                      <jats:sup>+<\/jats:sup>\n                      CD38\n                      <jats:sup>\u2212<\/jats:sup>\n                      CD133\n                      <jats:sup>+<\/jats:sup>\n                      cells in bone marrow samples from patients with hematological malignancies and healthy controls, using four-color flow cytometry.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      Interestingly, the CD45\n                      <jats:sup>dim<\/jats:sup>\n                      CD34\n                      <jats:sup>+<\/jats:sup>\n                      CD38\n                      <jats:sup>\u2212<\/jats:sup>\n                      CD133\n                      <jats:sup>+<\/jats:sup>\n                      cells were highly expressed in the bone marrow of patients with AML compared to that in healthy controls (HC). Moreover, the proportions of CD45\n                      <jats:sup>dim<\/jats:sup>\n                      CD34\n                      <jats:sup>+<\/jats:sup>\n                      CD38\n                      <jats:sup>\u2212<\/jats:sup>\n                      CD133\n                      <jats:sup>+<\/jats:sup>\n                      cells were also examined in diverse hematological malignancies, including AML, CML, DLBCL, MM, MDS, HL, ALL, and CLL. LSCs were prominently detected in the BMCs isolated from patients with AML and CML, but rarely in BMCs isolated from patients with DLBCL, MM, MDS, ALL, CLL, and HL. Additionally, the high CD45\n                      <jats:sup>dim<\/jats:sup>\n                      CD34\n                      <jats:sup>+<\/jats:sup>\n                      CD38\n                      <jats:sup>\u2212<\/jats:sup>\n                      CD133\n                      <jats:sup>+<\/jats:sup>\n                      cell counts in AML patients served as a significantly poor risk factor for overall and event free survival.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>\n                      Therefore, our results suggest that CD45\n                      <jats:sup>dim<\/jats:sup>\n                      CD34\n                      <jats:sup>+<\/jats:sup>\n                      CD38\n                      <jats:sup>\u2212<\/jats:sup>\n                      CD133\n                      <jats:sup>+<\/jats:sup>\n                      cells in AML might potentially serve as LSCs. In addition, this cell population might represent a novel therapeutic target in AML.\n                    <\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s12885-020-06760-1","type":"journal-article","created":{"date-parts":[[2020,4,6]],"date-time":"2020-04-06T12:03:57Z","timestamp":1586174637000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":28,"title":["CD45dimCD34+CD38\u2212CD133+ cells have the potential as leukemic stem cells in acute myeloid leukemia"],"prefix":"10.1186","volume":"20","author":[{"given":"Sook-Kyoung","family":"Heo","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eui-Kyu","family":"Noh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lan Jeong","family":"Ju","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jun Young","family":"Sung","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yoo Kyung","family":"Jeong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jaekyung","family":"Cheon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Su Jin","family":"Koh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Young Joo","family":"Min","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yunsuk","family":"Choi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jae-Cheol","family":"Jo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2020,4,6]]},"reference":[{"key":"6760_CR1","doi-asserted-by":"publisher","first-page":"e107587","DOI":"10.1371\/journal.pone.0107587","volume":"9","author":"M Terwijn","year":"2014","unstructured":"Terwijn M, Zeijlemaker W, Kelder A, Rutten AP, Snel AN, Scholten WJ, Pabst T, Verhoef G, Lowenberg B, Zweegman S, et al. Leukemic stem cell frequency: a strong biomarker for clinical outcome in acute myeloid leukemia. PLoS One. 2014;9:e107587.","journal-title":"PLoS One"},{"key":"6760_CR2","doi-asserted-by":"publisher","first-page":"52","DOI":"10.1038\/s41408-018-0087-2","volume":"8","author":"I Laverdiere","year":"2018","unstructured":"Laverdiere I, Boileau M, Neumann AL, Frison H, Mitchell A, Ng SWK, Wang JCY, Minden MD, Eppert K. Leukemic stem cell signatures identify novel therapeutics targeting acute myeloid leukemia. Blood Cancer J. 2018;8:52.","journal-title":"Blood Cancer J"},{"key":"6760_CR3","doi-asserted-by":"publisher","first-page":"326","DOI":"10.1053\/j.seminoncol.2008.04.003","volume":"35","author":"WI Chan","year":"2008","unstructured":"Chan WI, Huntly BJ. Leukemia stem cells in acute myeloid leukemia. Semin Oncol. 2008;35:326\u201335.","journal-title":"Semin Oncol"},{"key":"6760_CR4","doi-asserted-by":"publisher","first-page":"711","DOI":"10.1097\/CCO.0b013e328358f62d","volume":"24","author":"GJ Roboz","year":"2012","unstructured":"Roboz GJ. Current treatment of acute myeloid leukemia. Curr Opin Oncol. 2012;24:711\u20139.","journal-title":"Curr Opin Oncol"},{"key":"6760_CR5","doi-asserted-by":"publisher","first-page":"3977","DOI":"10.1158\/1078-0432.CCR-14-3186","volume":"21","author":"DF Angelini","year":"2015","unstructured":"Angelini DF, Ottone T, Guerrera G, Lavorgna S, Cittadini M, Buccisano F, De Bardi M, Gargano F, Maurillo L, Divona M, et al. A leukemia-associated CD34\/CD123\/CD25\/CD99+ Immunophenotype identifies FLT3-mutated clones in acute myeloid leukemia. Clin Cancer Res. 2015;21:3977\u201385.","journal-title":"Clin Cancer Res"},{"key":"6760_CR6","doi-asserted-by":"publisher","first-page":"105","DOI":"10.1038\/35102167","volume":"414","author":"T Reya","year":"2001","unstructured":"Reya T, Morrison SJ, Clarke MF, Weissman IL. Stem cells, cancer, and cancer stem cells. Nature. 2001;414:105\u201311.","journal-title":"Nature"},{"key":"6760_CR7","doi-asserted-by":"publisher","first-page":"1203","DOI":"10.1038\/labinvest.3700488","volume":"86","author":"BT Tan","year":"2006","unstructured":"Tan BT, Park CY, Ailles LE, Weissman IL. The cancer stem cell hypothesis: a work in progress. Lab Investig. 2006;86:1203\u20137.","journal-title":"Lab Investig"},{"key":"6760_CR8","doi-asserted-by":"publisher","first-page":"2659","DOI":"10.1182\/blood-2007-03-083048","volume":"110","author":"A van Rhenen","year":"2007","unstructured":"van Rhenen A, van Dongen GA, Kelder A, Rombouts EJ, Feller N, Moshaver B, Stigter-van Walsum M, Zweegman S, Ossenkoppele GJ, Jan Schuurhuis G. The novel AML stem cell associated antigen CLL-1 aids in discrimination between normal and leukemic stem cells. Blood. 2007;110:2659\u201366.","journal-title":"Blood"},{"key":"6760_CR9","doi-asserted-by":"publisher","first-page":"1700","DOI":"10.1038\/sj.leu.2404754","volume":"21","author":"A van Rhenen","year":"2007","unstructured":"van Rhenen A, Moshaver B, Kelder A, Feller N, Nieuwint AW, Zweegman S, Ossenkoppele GJ, Schuurhuis GJ. Aberrant marker expression patterns on the CD34+CD38- stem cell compartment in acute myeloid leukemia allows to distinguish the malignant from the normal stem cell compartment both at diagnosis and in remission. Leukemia. 2007;21:1700\u20137.","journal-title":"Leukemia"},{"key":"6760_CR10","doi-asserted-by":"publisher","first-page":"527","DOI":"10.1007\/s12032-013-0527-6","volume":"30","author":"FM Tolba","year":"2013","unstructured":"Tolba FM, Foda ME, Kamal HM, Elshabrawy DA. Expression of CD133 in acute leukemia. Med Oncol. 2013;30:527.","journal-title":"Med Oncol"},{"key":"6760_CR11","doi-asserted-by":"publisher","first-page":"730","DOI":"10.1038\/nm0797-730","volume":"3","author":"D Bonnet","year":"1997","unstructured":"Bonnet D, Dick JE. Human acute myeloid leukemia is organized as a hierarchy that originates from a primitive hematopoietic cell. Nat Med. 1997;3:730\u20137.","journal-title":"Nat Med"},{"key":"6760_CR12","doi-asserted-by":"publisher","first-page":"645","DOI":"10.1038\/367645a0","volume":"367","author":"T Lapidot","year":"1994","unstructured":"Lapidot T, Sirard C, Vormoor J, Murdoch B, Hoang T, Caceres-Cortes J, Minden M, Paterson B, Caligiuri MA, Dick JE. A cell initiating human acute myeloid leukaemia after transplantation into SCID mice. Nature. 1994;367:645\u20138.","journal-title":"Nature"},{"key":"6760_CR13","doi-asserted-by":"publisher","first-page":"568","DOI":"10.1182\/blood-2007-10-118331","volume":"112","author":"DC Taussig","year":"2008","unstructured":"Taussig DC, Miraki-Moud F, Anjos-Afonso F, Pearce DJ, Allen K, Ridler C, Lillington D, Oakervee H, Cavenagh J, Agrawal SG, et al. Anti-CD38 antibody-mediated clearance of human repopulating cells masks the heterogeneity of leukemia-initiating cells. Blood. 2008;112:568\u201375.","journal-title":"Blood"},{"key":"6760_CR14","doi-asserted-by":"publisher","first-page":"e1964","DOI":"10.1038\/cddis.2015.313","volume":"6","author":"EK Park","year":"2015","unstructured":"Park EK, Lee JC, Park JW, Bang SY, Yi SA, Kim BK, Park JH, Kwon SH, You JS, Nam SW, et al. Transcriptional repression of cancer stem cell marker CD133 by tumor suppressor p53. Cell Death Dis. 2015;6:e1964.","journal-title":"Cell Death Dis"},{"key":"6760_CR15","first-page":"470","volume":"15","author":"W Wang","year":"2007","unstructured":"Wang W, Wang HY, Zhao HX, Cui ZG, Li GL. Expression of CD133 in bone marrow cells of patients with leukemia and myelodysplastic syndrome. Zhongguo Shi Yan Xue Ye Xue Za Zhi. 2007;15:470\u20133.","journal-title":"Zhongguo Shi Yan Xue Ye Xue Za Zhi"},{"key":"6760_CR16","doi-asserted-by":"publisher","first-page":"530","DOI":"10.1016\/j.scr.2015.09.008","volume":"15","author":"H Reikvam","year":"2015","unstructured":"Reikvam H, Brenner AK, Hagen KM, Liseth K, Skrede S, Hatfield KJ, Bruserud O. The cytokine-mediated crosstalk between primary human acute myeloid cells and mesenchymal stem cells alters the local cytokine network and the global gene expression profile of the mesenchymal cells. Stem Cell Res. 2015;15:530\u201341.","journal-title":"Stem Cell Res"},{"key":"6760_CR17","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1186\/s13045-016-0292-z","volume":"9","author":"A Al-Mawali","year":"2016","unstructured":"Al-Mawali A, Gillis D, Lewis I. Immunoprofiling of leukemic stem cells CD34+\/CD38\u2212\/CD123+ delineate FLT3\/ITD-positive clones. J Hematol Oncol. 2016;9:61.","journal-title":"J Hematol Oncol"},{"key":"6760_CR18","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1111\/j.1365-2362.2007.01746.x","volume":"37","author":"AW Hauswirth","year":"2007","unstructured":"Hauswirth AW, Florian S, Printz D, Sotlar K, Krauth MT, Fritsch G, Schernthaner GH, Wacheck V, Selzer E, Sperr WR, Valent P. Expression of the target receptor CD33 in CD34+\/CD38\u2212\/CD123+ AML stem cells. Eur J Clin Investig. 2007;37:73\u201382.","journal-title":"Eur J Clin Investig"},{"key":"6760_CR19","doi-asserted-by":"publisher","first-page":"137","DOI":"10.1179\/102453308X316103","volume":"13","author":"M Guenova","year":"2008","unstructured":"Guenova M, Balatzenko G. CD133-2 (AC141) expression analysis in acute leukemia immunophenotyping in correlation to CD34 and P-glycoprotein. Hematology. 2008;13:137\u201341.","journal-title":"Hematology"},{"key":"6760_CR20","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1016\/j.cytogfr.2018.08.004","volume":"43","author":"S Binder","year":"2018","unstructured":"Binder S, Luciano M, Horejs-Hoeck J. The cytokine network in acute myeloid leukemia (AML): a focus on pro- and anti-inflammatory mediators. Cytokine Growth Factor Rev. 2018;43:8\u201315.","journal-title":"Cytokine Growth Factor Rev"},{"key":"6760_CR21","doi-asserted-by":"publisher","first-page":"1142","DOI":"10.1634\/stemcells.2004-0317","volume":"23","author":"A Toren","year":"2005","unstructured":"Toren A, Bielorai B, Jacob-Hirsch J, Fisher T, Kreiser D, Moran O, Zeligson S, Givol D, Yitzhaky A, Itskovitz-Eldor J, et al. CD133-positive hematopoietic stem cell \"stemness\" genes contain many genes mutated or abnormally expressed in leukemia. Stem Cells. 2005;23:1142\u201353.","journal-title":"Stem Cells"},{"key":"6760_CR22","doi-asserted-by":"publisher","first-page":"1929","DOI":"10.1158\/0008-5472.CAN-11-3589","volume":"72","author":"AB Mak","year":"2012","unstructured":"Mak AB, Nixon AM, Moffat J. The mixed lineage leukemia (MLL) fusion-associated gene AF4 promotes CD133 transcription. Cancer Res. 2012;72:1929\u201334.","journal-title":"Cancer Res"},{"key":"6760_CR23","doi-asserted-by":"publisher","first-page":"e98859","DOI":"10.1371\/journal.pone.0098859","volume":"9","author":"SK Heo","year":"2014","unstructured":"Heo SK, Noh EK, Yoon DJ, Jo JC, Park JH, Kim H. Dasatinib accelerates valproic acid-induced acute myeloid leukemia cell death by regulation of differentiation capacity. PLoS One. 2014;9:e98859.","journal-title":"PLoS One"},{"key":"6760_CR24","doi-asserted-by":"publisher","first-page":"2284","DOI":"10.2741\/4052","volume":"17","author":"P Li","year":"2012","unstructured":"Li P, Ji M, Park J, Bunting KD, Ji C, Tse W. Th17 related cytokines in acute myeloid leukemia. Front Biosci (Landmark Ed). 2012;17:2284\u201394.","journal-title":"Front Biosci (Landmark Ed)"},{"key":"6760_CR25","doi-asserted-by":"publisher","first-page":"933","DOI":"10.1111\/cas.12459","volume":"105","author":"Y Han","year":"2014","unstructured":"Han Y, Ye A, Bi L, Wu J, Yu K, Zhang S. Th17 cells and interleukin-17 increase with poor prognosis in patients with acute myeloid leukemia. Cancer Sci. 2014;105:933\u201342.","journal-title":"Cancer Sci"},{"key":"6760_CR26","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1146\/annurev.cb.11.110195.000343","volume":"11","author":"SJ Morrison","year":"1995","unstructured":"Morrison SJ, Uchida N, Weissman IL. The biology of hematopoietic stem cells. Annu Rev Cell Dev Biol. 1995;11:35\u201371.","journal-title":"Annu Rev Cell Dev Biol"},{"key":"6760_CR27","doi-asserted-by":"publisher","first-page":"157","DOI":"10.1016\/S0092-8674(00)81692-X","volume":"100","author":"IL Weissman","year":"2000","unstructured":"Weissman IL. Stem cells: units of development, units of regeneration, and units in evolution. Cell. 2000;100:157\u201368.","journal-title":"Cell"},{"key":"6760_CR28","doi-asserted-by":"publisher","first-page":"3983","DOI":"10.1073\/pnas.0530291100","volume":"100","author":"M Al-Hajj","year":"2003","unstructured":"Al-Hajj M, Wicha MS, Benito-Hernandez A, Morrison SJ, Clarke MF. Prospective identification of tumorigenic breast cancer cells. Proc Natl Acad Sci U S A. 2003;100:3983\u20138.","journal-title":"Proc Natl Acad Sci U S A"},{"key":"6760_CR29","doi-asserted-by":"publisher","first-page":"e5163","DOI":"10.1097\/MD.0000000000005163","volume":"95","author":"L Lu","year":"2016","unstructured":"Lu L, Wu M, Sun L, Li W, Fu W, Zhang X, Liu T. Clinicopathological and prognostic significance of cancer stem cell markers CD44 and CD133 in patients with gastric cancer: a comprehensive meta-analysis with 4729 patients involved. Medicine (Baltimore). 2016;95:e5163.","journal-title":"Medicine (Baltimore)"},{"key":"6760_CR30","doi-asserted-by":"publisher","first-page":"1650","DOI":"10.1126\/science.1186624","volume":"327","author":"Y Wang","year":"2010","unstructured":"Wang Y, Krivtsov AV, Sinha AU, North TE, Goessling W, Feng Z, Zon LI, Armstrong SA. The Wnt\/beta-catenin pathway is required for the development of leukemia stem cells in AML. Science. 2010;327:1650\u20133.","journal-title":"Science"},{"issue":"Suppl 2","key":"6760_CR31","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1111\/j.0960-135X.2004.01368.x","volume":"34","author":"WR Sperr","year":"2004","unstructured":"Sperr WR, Hauswirth AW, Florian S, Ohler L, Geissler K, Valent P. Human leukaemic stem cells: a novel target of therapy. Eur J Clin Investig. 2004;34(Suppl 2):31\u201340.","journal-title":"Eur J Clin Investig"},{"key":"6760_CR32","doi-asserted-by":"publisher","unstructured":"Joseph C, Arshad M, Kurozomi S, Althobiti M, Miligy IM, Al-Izzi S, Toss MS, Goh FQ, Johnston SJ, Martin SG, Ellis IO, Mongan NP, Green AR, Rakha EA. Overexpression of the cancer stem cell marker CD133 confers a poor prognosis in invasive breast cancer. Breast Cancer Res Treat. 2019;174(2):387\u201399. https:\/\/doi.org\/10.1007\/s10549-018-05085-9.","DOI":"10.1007\/s10549-018-05085-9"},{"key":"6760_CR33","doi-asserted-by":"publisher","first-page":"396","DOI":"10.1038\/nature03128","volume":"432","author":"SK Singh","year":"2004","unstructured":"Singh SK, Hawkins C, Clarke ID, Squire JA, Bayani J, Hide T, Henkelman RM, Cusimano MD, Dirks PB. Identification of human brain tumour initiating cells. Nature. 2004;432:396\u2013401.","journal-title":"Nature"},{"key":"6760_CR34","doi-asserted-by":"publisher","first-page":"1127","DOI":"10.1089\/scd.2008.0338","volume":"18","author":"Y Wu","year":"2009","unstructured":"Wu Y, Wu PY. CD133 as a marker for cancer stem cells: progresses and concerns. Stem Cells Dev. 2009;18:1127\u201334.","journal-title":"Stem Cells Dev"},{"key":"6760_CR35","doi-asserted-by":"publisher","first-page":"3204","DOI":"10.1016\/j.celrep.2017.03.018","volume":"18","author":"A Carey","year":"2017","unstructured":"Carey A, Edwards DK, Eide CA, Newell L, Traer E, Medeiros BC, Pollyea DA, Deininger MW, Collins RH, Tyner JW, et al. Identification of Interleukin-1 by functional screening as a key mediator of cellular expansion and disease progression in acute myeloid leukemia. Cell Rep. 2017;18:3204\u201318.","journal-title":"Cell Rep"},{"key":"6760_CR36","doi-asserted-by":"publisher","first-page":"e55473","DOI":"10.1371\/journal.pone.0055473","volume":"8","author":"X Qian","year":"2013","unstructured":"Qian X, Cao S, Yang G, Pan Y, Yin C, Chen X, Zhu Y, Zhuang Y, Shen Y, Hu Z. Potentially functional polymorphism in IL-23 receptor and risk of acute myeloid leukemia in a Chinese population. PLoS One. 2013;8:e55473.","journal-title":"PLoS One"}],"container-title":["BMC Cancer"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s12885-020-06760-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1186\/s12885-020-06760-1\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s12885-020-06760-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,4,5]],"date-time":"2021-04-05T19:15:30Z","timestamp":1617650130000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmccancer.biomedcentral.com\/articles\/10.1186\/s12885-020-06760-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,4,6]]},"references-count":36,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2020,12]]}},"alternative-id":["6760"],"URL":"https:\/\/doi.org\/10.1186\/s12885-020-06760-1","relation":{"has-preprint":[{"id-type":"doi","id":"10.21203\/rs.2.15973\/v3","asserted-by":"object"},{"id-type":"doi","id":"10.21203\/rs.2.15973\/v1","asserted-by":"object"},{"id-type":"doi","id":"10.21203\/rs.2.15973\/v2","asserted-by":"object"}]},"ISSN":["1471-2407"],"issn-type":[{"value":"1471-2407","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,4,6]]},"assertion":[{"value":"2 October 2019","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 March 2020","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 April 2020","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"All experiments were performed in accordance with the relevant guidelines and regulations. All patients provided written informed consent before the commencement of the study. The study protocol and patient informed consent form were approved by the Ulsan University Hospital Ethics Committee and Institutional Review Board (UUH-IRB-2016-07-026). The informed written consent was obtained from all included subjects before collecting the bone marrow samples.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare that no competing interests exist.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"285"}}